Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02826382 · ClinicalTrials.gov registry record · Early Phase 1
Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041
A Early Phase 1 study, sponsored by Five Eleven Pharma.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 14
- Enrollment target
NCT02826382: Completed Early Phase 1 study, sponsored by Five Eleven Pharma.
NCT02826382 is a Early Phase 1 study that has completed, run by Five Eleven Pharma. The registered enrollment target is 14 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02826382, a Early Phase 1 study, has completed, sponsored by Five Eleven Pharma.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
A phase1 study to demonstrate \[68Ga\]P15-041 binding to bone metastases in prostate cancer and determination of human dosimetry.
Primary Outcome
kinetics of \[68Ga\]P15-041 uptake in known or suspected bone metastases in prostate cancer
Interventions
- DRUG [68Ga]P15-041
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2016-09-20 |
| Est. Completion | 2022-12-31 |
| Phase | Early Phase 1 |
What the finished NCT02826382 record still lists
NCT02826382 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 1 intervention - of which [68Ga]P15-041 is the first listed.
NCT02826382 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02826382 about?
NCT02826382 is a clinical study titled "Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041". A phase1 study to demonstrate \[68Ga\]P15-041 binding to bone metastases in prostate cancer and determination of human dosimetry.
What is the current status of trial NCT02826382?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 14 participants. The study started on 2016-09-20. Estimated completion is 2022-12-31.
What interventions are being tested in trial NCT02826382?
The interventions under investigation include: [68Ga]P15-041 (DRUG).
Who is sponsoring clinical trial NCT02826382?
This trial is sponsored by Five Eleven Pharma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02826382's enrollment target sits among peer trials
14 1475th of 2000 higher than 498 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy